tci Medicare Compliance & Reimbursement - 2003 Issue 17
Medicaid Drugs: LEGISLATIVE OFFICE URGES FLORIDA TO DUMP PFIZER MEDICAID PROGRAM
Subscribe or sign in to view the full article.
Article Overview
This article covers a Florida legislative watchdog review of Medicaid drug purchasing and preferred-drug list arrangements. It contrasts supplemental cash rebate approaches with manufacturer value-added programs, discusses the state agency’s response, and summarizes the policy debate over whether these programs are producing measurable savings. The piece is relevant to Medicaid administrators, pharmacy benefit and rebate stakeholders, government auditors, and health policy readers following drug-list management and manufacturer agreements.
Why This Topic Matters
It explains a state-level assessment of Medicaid drug contracting strategy and why lawmakers were questioning whether manufacturer service-based arrangements were delivering verifiable fiscal benefits. The article is useful for understanding how rebate structures and preferred-drug list policies can affect Medicaid spending oversight.
What You Will Learn
- How Florida Medicaid preferred-drug list arrangements are being evaluated
- The difference between rebate-based and value-added manufacturer agreements
- Why a state oversight report questioned the savings from certain Medicaid drug programs
- How the state agency responded to the report's findings
- Which manufacturer programs were discussed in the context of Florida Medicaid
Who Should Read This
- Medicaid program administrators
- Health policy analysts
- Pharmacy benefit managers
- Government auditors and compliance staff
- Pharmaceutical contract and rebate professionals
- Medical billing and coding researchers
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com